All News
Filter News
Found 9,535 articles
-
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
4/15/2024
IO Biotech today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial.
-
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
4/15/2024
Viatris Inc. today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
U.S. Gene Therapy Market Size, Share & Growth Report, 2033
4/12/2024
According to Nova One Advisor, the U.S. gene therapy market size was valued at USD 3.19 billion in 2023
-
Engineered T Cells Market Size, Growth, Trends and Forecast 2024-2033
4/11/2024
The global engineered T cells market size was estimated at USD 26.87 billion in 2023 and is projected to hit around USD 348.9 billion by 2032, growing at a CAGR of 32.96% from 2023 to 2032.
-
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
4/11/2024
FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.
-
Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board
4/10/2024
Nodexus Inc. today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).
-
Even with discounts that reach as high as 86%, Humira biosimilars are finding it difficult to take market share away from the AbbVie blockbuster, according to a new report from Samsung Bioepis.
-
Genetic Testing Market Size to Set USD 64.73 Billion by 2033
4/8/2024
According to Vision Research Reports, the global genetic testing market size was estimated at around USD 8.84 billion in 2023 and it is projected to set around USD 64.73 billion by 2033 with a CAGR of 22.03% from 2024 to 2033.
-
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
4/8/2024
CytomX Therapeutics, Inc. today announced the first patient has been dosed in a Phase 1 dose escalation study ( NCT06265688 ) of CX-2051 in patients with advanced solid tumors.
-
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
4/8/2024
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California.
-
Zura Bio Announces Robert Lisicki as CEO and Director
4/8/2024
Zura Bio Limited a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.
-
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
4/8/2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible.
-
Opthea Appoints John Han, PharmD, as VP Medical AffairsBrings extensive experience in retinal and ophthalmology diseases
4/8/2024
Opthea Limited announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024.
-
Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.
-
Seeking a potential slice of the challenging KRAS market, Merck has launched a Phase III NSCLC trial of its oral G12C inhibitor MK-1084, in combination with Keytruda, in pursuit of Amgen and Bristol Myers Squibb.
-
Due to slow uptake of its Humira biosimilar Cyltezo in the U.S., Boehringer Ingelheim is laying off an undisclosed number of its sales employees, Reuters reported on Thursday.
-
U.S. Cell And Gene Therapy Clinical Trial Services industry is Rising Rapidly
4/5/2024
The U.S. cell and gene therapy clinical trial services market size was valued at USD 9.10 billion in 2023 and is anticipated to reach around USD 71.54 billion by 2033, growing at a CAGR of 22.9% from 2024 to 2033.
-
U.S. Life Science Tools Market Size To Hit USD 140.44 Bn By 2033
4/5/2024
According to the latest research by nova one advisor, the U.S. life science tools market size was valued at USD 57.19 billion in 2023 and is estimated to hit around USD 140.44 billion by 2033, growing at a noteworthy CAGR of 9.4% from 2024 to 2033.
-
Cell and Gene Therapy Market Size to Reach USD 97.33 Bn by 2033
4/5/2024
According to the latest research by nova one advisor, the global cell and gene therapy market size was valued at USD 18.13 billion in 2023 and is anticipated to reach around USD 97.33 billion by 2033, growing at a CAGR of 18.3% from 2024 to 2033.